Literature DB >> 23746340

A case of oculoglandular tularemia resistant to medical treatment.

Muhammet Kosker1, Dicle Sener, Omer Kilic, Ferit Akil, Mehmet Yilmaz, Ozcan Ozturk, Haluk Cokugras, Yildiz Camcioglu, Necla Akcakaya.   

Abstract

Tularemia is a zoonotic disease of the northern hemisphere. Oculoglandular tularemia is the rarest form, comprising 1.4-4.2% of all cases. We present a patient with oculoglandular tularemia that did not respond to gentamicin to demonstrate the need for prolonged antimicrobial treatment and surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746340     DOI: 10.3109/00365548.2013.796089

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

1.  AR-13, a Celecoxib Derivative, Directly Kills Francisella In Vitro and Aids Clearance and Mouse Survival In Vivo.

Authors:  Ky V Hoang; Haley E Adcox; James R Fitch; David M Gordon; Heather M Curry; Larry S Schlesinger; Peter White; John S Gunn
Journal:  Front Microbiol       Date:  2017-09-11       Impact factor: 5.640

2.  Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge.

Authors:  Ky V Hoang; Heather Curry; Michael A Collier; Hassan Borteh; Eric M Bachelder; Larry S Schlesinger; John S Gunn; Kristy M Ainslie
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

3.  Treatment-failure tularemia in children.

Authors:  Arzu Karlı; Gülnar Şensoy; Şule Paksu; Muhammet Furkan Korkmaz; Ömer Ertuğrul; Rıfat Karlı
Journal:  Korean J Pediatr       Date:  2018-02-28

Review 4.  New therapeutic approaches for treatment of tularaemia: a review.

Authors:  Sandrine Boisset; Yvan Caspar; Vivien Sutera; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-03-28       Impact factor: 5.293

5.  Inhibition of Francisella tularensis phagocytosis using a novel anti-LPS scFv antibody fragment.

Authors:  Adva Mechaly; Uri Elia; Ron Alcalay; Hila Cohen; Eyal Epstein; Ofer Cohen; Ohad Mazor
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.